重组人白细胞介素-11与海曲泊帕乙醇胺片对乳腺癌化疗所致血小板减少症的疗效对比

doi:10.11958/20241463

天津医药 ›› 2025, Vol. 53 ›› Issue (4): 365-369.doi: 10.11958/20241463

重组人白细胞介素-11与海曲泊帕乙醇胺片对乳腺癌化疗所致血小板减少症的疗效对比

王超¹(), 张俊梅², 张鹏¹, 刘力¹^,^△(), 王晓春¹

1 河北大学附属医院乳腺外科（邮编071000）
2 滦南县医院病理科

收稿日期:2024-10-09 修回日期:2025-02-05 出版日期:2025-04-15 发布日期:2025-04-17
通讯作者: ^△ E-mail：xxpog28@163.com
作者简介:王超（1982），男，主治医师，主要从事乳腺疾病的诊治方面研究。E-mail：omeua8@163.com
基金资助:
河北省医学科学研究课题计划项目(20231500)

Comparison of efficacy of recombinant human interleukin-11 and herombopag olamine tablets on chemotherapy-induced thrombocytopenia in breast cancer

WANG Chao¹(), ZHANG Junmei², ZHANG Peng¹, LIU Li¹^,^△(), WANG Xiaochun¹

1 Department of Breast Surgery, Hebei University Affiliated Hospital, Baoding 071000, China
2 Department of Pathology, Luannan County Hospital

Received:2024-10-09 Revised:2025-02-05 Published:2025-04-15 Online:2025-04-17
Contact: ^△ E-mail：xxpog28@163.com

王超, 张俊梅, 张鹏, 刘力, 王晓春. 重组人白细胞介素-11与海曲泊帕乙醇胺片对乳腺癌化疗所致血小板减少症的疗效对比[J]. 天津医药, 2025, 53(4): 365-369.

WANG Chao, ZHANG Junmei, ZHANG Peng, LIU Li, WANG Xiaochun. Comparison of efficacy of recombinant human interleukin-11 and herombopag olamine tablets on chemotherapy-induced thrombocytopenia in breast cancer[J]. Tianjin Medical Journal, 2025, 53(4): 365-369.

摘要/Abstract

摘要：

目的对比重组人白细胞介素-11（rhIL-11）与海曲泊帕乙醇胺片治疗乳腺癌化疗所致血小板减少症（CIT）的疗效。方法前瞻性选择乳腺癌CIT患者86例，随机分为对照组（给予rhIL-11）和研究组（给予海曲泊帕乙醇胺片），2组各43例。治疗前和治疗14 d后，采用全自动血液分析仪检测血小板参数[血小板计数（PLT）、血小板压积（PCT）、血小板分布宽度（PDW）、平均血小板体积（MPV）]，流式细胞仪检测细胞免疫指标（CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺），酶联免疫吸附试验检测血小板生成素（TPO）、白细胞介素-11（IL-11），比较2组间和每组治疗前后上述指标水平，并记录2组不良反应发生情况。结果治疗后，2组患者PLT、PCT、CD3⁺、CD4⁺、CD4⁺/CD8⁺、TPO、IL-11均高于治疗前，且研究组高于对照组（P<0.05）；2组治疗后的PDW、MPV、CD8⁺均低于治疗前，且研究组低于对照组（P<0.05）。2组不良反应总发生率差异无统计学意义（P>0.05）。结论 rhIL-11、海曲泊帕乙醇胺片治疗乳腺癌CIT均有效，海曲泊帕乙醇胺片在改善血小板参数、细胞免疫指标、TPO、IL-11方面较rhIL-11更具优势，且未增加不良反应的发生。

关键词: 白细胞介素11, 乙醇胺, 血小板减少, 乳腺肿瘤, 海曲泊帕乙醇胺片

Abstract:

Objective To compare the efficacy of recombinant human interleukin-11 (rhIL-11) and herombopag olamine tablets on chemotherapy-induced thrombocytopenia (CIT) in breast cancer. Methods Eighty-six prospectively selected breast cancer patients with CIT were randomly divided into the control group (administered rhIL-11) and the study group (administered herombopag olamine tablets), with 43 cases in each group. Before treatment and 14 days after treatment, platelet parameters [platelet count (PLT), plateletcrit (PCT), platelet distribution width (PDW) and mean platelet volume (MPV)] and flow cytometry were measured by automated hematology analyzer. Cellular immune indicators (CD3⁺, CD4⁺, CD8⁺and CD4⁺/CD8⁺) were detected by flow cytometer. Enzyme-linked immunosorbent assay was used to determine the levels of thrombopoietin (TPO) and interleukin-11 (IL-11). The above parameters were compared between the two groups, and the incidence of adverse reactions in the two groups was recorded. Results After treatment, PLT, PCT, CD3⁺, CD4⁺, CD4⁺/CD8⁺, TPO and IL-11 in both groups were higher than before treatment, and which was higher in the study group than the control group (P<0.05). After treatment, PDW, MPV and CD8⁺of both groups were lower than before treatment, and the study group was lower than the control group (P<0.05). There was no significant difference in the overall incidence of adverse reactions between the two groups (P>0.05). Conclusion Both rhIL-11 and herombopag olamine tablets are effective in treating breast cancer with CIT. Compared with rhIL-11, herombopag olamine tablets have more advantages in improving platelet parameters, cellular immune indicators, TPO and IL-11, and do not increase the adverse reactions.

Key words: interleukin-11, ethanolamine, thrombocytopenia, breast neoplasms, herombopag olamine tablets

中图分类号:

R969.4

图/表 4

参考文献 20

[1]	陈芷彦, 伍秋苑, 邓裕华, 等. 类器官技术在乳腺癌研究中的现状及应用[J]. 天津医药, 2024, 52(6):668-672.
	CHEN Z Y, WU Q Y, DENG Y H, et al. Status and application of organoid technology in breast cancer research[J]. Tianjin Med J, 2024, 52(6):668-672. doi:10.11958/20231745.
[2]	中国抗癌协会乳腺癌专业委员会, 中华医学会肿瘤学分会乳腺肿瘤学组,邵志敏. 中国抗癌协会乳腺癌诊治指南与规范(2024年版)[J]. 中国癌症杂志, 2023, 33(12):1092-1186.
	Breast Cancer Professional Committee of China Anti Cancer Association,Breast Oncology Group, Oncology Branch,Chinese Medical Association,SHAO Z M. Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association(2024 edition)[J]. China Oncol, 2023, 33(12):1092-1186. doi:10.19401/j.cnki.1007-3639.2023.12.004.
[3]	中华医学会肿瘤学分会肿瘤支持康复治疗学组. 肿瘤治疗相关血小板减少症的临床管理专家共识[J]. 肿瘤, 2021, 41(12):812-827.
	Tumor Support Rehabilitation Therapy Group of the Oncology Branch of the Chinese Medical Association. Consensus on clinical management of cancer therapy-related thrombocytopenia[J]. Tumor, 2021, 41(12):812-827. doi:10.3781/j.issn.1000-7431.2021.2111-0882.
[4]	中国临床肿瘤学会肿瘤化疗所致血小板减少症共识专家委员会. 肿瘤化疗所致血小板减少症诊疗中国专家共识(2018版)[J]. 中华肿瘤杂志, 2018, 40(9):714-720.
	Consensus Expert Committee on Thrombocytopenia Caused by Tumor Chemotherapy of the Chinese Society of Clinical Oncology. Consensus on clinical diagnosis,treatment and prevention management of chemotherapy induced thrombocytopenia in China(2018)[J]. Chin J Oncol, 2018, 40(9):714-720. doi:10.3760/cma.j.issn.0253-3766.2018.09.014.
[5]	常丽, 孙素芹, 任宏, 等. 重组人白细胞介素-11对恶性实体瘤患者化疗所致血小板减少症一级预防的有效性和安全性[J]. 癌症进展, 2023, 21(24):2710-2714.
	CHANG L, SUN S Q, REN H, et al. Efficacy and safety of recombinant human interleukin-11 in primary prevention of chemotherapy-induced thrombocytopenia in patients with malignant solid tumors[J]. Oncology Progress, 2023, 21(24):2710-2714. doi:10.11877/j.issn.1672-1535.2023.21.24.11.
[6]	中国临床肿瘤学会抗淋巴瘤联盟, 中国临床肿瘤学会抗白血病联盟, 中国临床肿瘤学会抗肿瘤药物安全管理专家委员会, 等. 重组人白介素-11防治血小板减少症临床应用中国专家共识(2021年版)[J]. 临床肿瘤学杂志, 2020, 25(12):1129-1137.
	Chinese Society of Clinical Oncology Anti Lymphoma Alliance,Chinese Society of Clinical Oncology Anti Leukemia Alliance, Expert Committee on Safety Management of Antitumor Drugs of the Chinese Society of Clinical Oncology, et al. Chinese expert consensus on the clinical application of recombinant human interleukin-11 in the prevention and treatment of thrombocytopenia (2021 Edition)[J]. Chin Clin Oncol, 2020, 25(12):1129-1137. doi:10.3969/j.issn.1009-0460.2020.12.014.
[7]	中国临床肿瘤学会(CSCO)抗肿瘤药物治疗安全管理专家委员会. 海曲泊帕临床应用指导原则[J]. 白血病·淋巴瘤, 2022, 31(10):577-582.
	Chinese Society of Clinical Oncology (CSCO) Expert Committee on Safety Management of Antitumor Drug Therapy. Guiding principles for clinical application of hetrombopag[J]. Journal of Leukemia and Lymphoma, 2022, 31(10):577-582. doi:10.3760/cma.j.cn115356-20220809-00229.
[8]	郁飞文, 彭猛青, 张茹茹, 等. 海曲泊帕乙醇胺片对抗肿瘤治疗后血小板减少症患者临床疗效及对血清TPO、STAT3、MAPK的影响[J]. 药物评价研究, 2023, 46(3):614-620.
	YU F W, PENG M Q, ZHANG R R, et al. Clinical efficacy and effect of Herombopag Olamine Tablets on serum TPO,STAT3 and MAPK in patients with thrombocytopenia after anti-tumor therapy[J]. Drug Eval Res, 2023, 46(3):614-620. doi:10.7501/j.issn.1674-6376.2023.03.020.
[9]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31(10):954-1040.
	Breast Cancer Professional Committee of China Anti Cancer Association. Guidelines and specifications for breast cancer diagnosis and treatment of China Anti Cancer Association (2021)[J]. China Oncol, 2021, 31(10):954-1040. doi:10.19401/j.cnki.1007-3639.2021.10.013.
[10]	中国抗癌协会肿瘤临床化疗专业委员会, 中国抗癌协会肿瘤支持治疗专业委员会. 中国肿瘤化疗相关性血小板减少症专家诊疗共识(2019版)[J]. 中国肿瘤临床, 2019, 46(18):923-929.
	Cancer Clinical Chemotherapy Professional Committee of China Anti Cancer Association,Cancer Support Therapy Professional Committee of China Anti Cancer Association. Consensus on the clinical diagnosis,treatment,and prevention of chemotherapy-in-duced thrombocytopenia in China (2019 version)[J]. Chin J Clin Oncol, 2019, 46(18):923-929. doi:10.3969/j.issn.1000-8179.2019.18.914.
[11]	客蕊, 张旭明, 迟庆滨. 中医药防治恶性肿瘤化疗后血小板减少症的研究进展[J]. 江苏中医药, 2021, 53(9):77-81.
	KE R, ZHANG X M, CHI Q B. Research progress on traditional Chinese medicine in the prevention and treatment of thrombocytopenia after chemotherapy for malignant tumors[J]. Jiangsu J Tradit Chin Med, 2021, 53(9):77-81. doi:10.19844/j.cnki.1672-397X.2021.09.026.
[12]	中华中医药学会血液病分会, 中国中西医结合学会肿瘤专业委员会, 北京中西医结合学会肿瘤专业委员会. 肿瘤化疗相关性血小板减少症中医药防治专家共识[J]. 北京中医药, 2021, 40(5):451-455.
	Hematology Branch of the Chinese Society of Traditional Chinese Medicine,Cancer Professional Committee of the Chinese Society of Integrated Traditional Chinese and Western Medicine, Cancer Professional Committee of Beijing Association of Traditional Chinese and Western Medicine. Expert consensus on traditional Chinese medicine prevention and treatment of tumor chemotherapy associated thrombocytopenia[J]. Beijing J Tradit Chin Med, 2021, 40(5):451-455. doi:10.16025/j.1674-1307.2021.05.002.
[13]	卫紫钰, 秦悦莹, 郭炎, 等. 肿瘤化疗相关性血小板减少症(CIT)药物治疗新进展[J]. 山东化工, 2023, 52(1):88-90.
	WEI Z Y, QIN Y Y, GUO Y, et al. New progress in drug therapy of tumor chemotherapy-associated thrombocytopenia(CIT)[J]. Shandong Chemical Industry, 2023, 52(1):88-90. doi:10.3969/j.issn.1008-021X.2023.01.025.
[14]	范海艳, 刘怡雯. 重组人血小板生成素、重组人白介素-11预防卵巢癌化疗患者血小板减少症的对比研究[J]. 药品评价, 2023, 20(2):237-240.
	FAN H Y, LIU Y W. Comparative study of recombinant human thrombopoietin and recombinant human interleukin-11 in preventing thrombocytopenia in patients with ovarian cancer undergoing chemotherapy[J]. Drug Eval, 2023, 20(2):237-240. doi:10.19939/j.cnki.1672-2809.2023.02.29.
[15]	王君萍, 黄玲玲, 张梅, 等. 海曲泊帕合理应用评价标准的建立与应用[J]. 中国医院用药评价与分析, 2023, 23(9):1127-1130.
	WANG J P, HUANG L L, ZHANG M, et al. Establishment and application of evaluation criteria for rational use of hetrombopag[J]. Evaluation and Analysis of Drug-Use in Hospitals of China, 2023, 23(9):1127-1130. doi:10.14009/j.issn.1672-2124.2023.09.020.
[16]	刘丹娜, 苏田丽, 吴通, 等. 基于文献分析药学监护对化疗相关性血小板减少症的作用及流程[J]. 中国药师, 2022, 25(7):1235-1239.
	LIU D N, SU T L, WU T, et al. Effects and procedures of pharmaceutical care in chemotherapy-induced thrombocytopenia based on lit-erature analysis[J]. Frontiers in Pharmaceutical Sciences, 2022, 25(7):1235-1239. doi:10.19962/j.cnki.issn1008-049X.2022.07.024.
[17]	莫峥, 于飞, 李利红, 等. 海曲泊帕治疗实体瘤化疗所致血小板减少症效果观察[J]. 肿瘤研究与临床, 2023, 35(9):703-705.
	MO Z, YU F, LI L H, et al. Efficacy observation of hetrombopag in treatment of chemotherapy-induced thrombocytopenia in solid tumors[J]. Cancer Research and Clinic, 2023, 35(9):703-705. doi:10.3760/cma.j.cn115355-20230324-00149.
[18]	宋雪雯. 第第一部分:促血小板生成素受体激动剂对慢性难治性ITP患者免疫稳态的调节及其临床预测价值;第二部分:中国血友病真实世界研究:一项天津市单中心研究[D]. 中国医学科学院北京协和医学院, 2020.
	SONG X W. Part One:Effect of thrombopoietin receptor agonists on regulation of immune homeostasis and its clinical predictive value in patients with chronic refractory ITP; Part Two:Real-world analysis of hemophilia patients in China:A single center's experience[D]. Peking Union Medical College, Chinese Academy of Medical Sciences, 2020. doi:10.27648/d.cnki.gzxhu.2020.000006.
[19]	杨凌妍, 刘秀梅, 沈曦凤, 等. 重组人白细胞介素-11药物利用评价标准建立与使用合理性分析[J]. 中国药物与临床, 2023, 23(3):143-149.
	YANG L Y, LIU X M, SHEN X F, et al. Establishment and rationality analysis of evaluation criteria for drug utilization of recombinant human interleukin-11[J]. Chin Remed & Clin, 2023, 23(3):143-149. doi:10.11655/zgywylc2023.03.002.
[20]	庞丽娜, 龚帅, 张胜利, 等. 海曲泊帕治疗恶性肿瘤化疗相关血小板减少的效果和安全性[J]. 河南医学研究, 2023, 32(22):4048-4051.
	PANG L N, GONG S, ZHANG S L, et al. Hetrombopag's efficacy and security in the treatment of thrombocytopenia by chemotherapy[J]. Henan Med Res, 2023, 32(22):4048-4051. doi:10.3969/j.issn.1004-437X.2023.22.004.

组别		PLT/（×10⁹/L）						PCT/%
组别		治疗前		治疗后		t		治疗前		治疗后	t
对照组		20.52±4.48		57.93±7.35		65.497^＊		0.08±0.02		0.17±0.05	21.482^＊
研究组		19.37±4.03		61.72±8.32		63.129^＊		0.09±0.03		0.20±0.07	19.019^＊
t		1.251		2.239^＊				1.819		2.287^＊
组别	PDW/%						MPV/fL
组别	治疗前		治疗后		t		治疗前		治疗后			t
对照组	32.62±6.38		20.08±5.34		25.080^＊		29.58±5.62		18.88±5.13			23.712^＊
研究组	33.28±6.63		17.81±4.48		30.266^＊		30.62±6.09		16.64±4.57			29.737^＊
t	0.470		2.136^＊				0.823		2.138^＊

组别		PLT/（×10⁹/L）						PCT/%
组别		治疗前		治疗后		t		治疗前		治疗后	t
对照组		20.52±4.48		57.93±7.35		65.497^＊		0.08±0.02		0.17±0.05	21.482^＊
研究组		19.37±4.03		61.72±8.32		63.129^＊		0.09±0.03		0.20±0.07	19.019^＊
t		1.251		2.239^＊				1.819		2.287^＊
组别	PDW/%						MPV/fL
组别	治疗前		治疗后		t		治疗前		治疗后			t
对照组	32.62±6.38		20.08±5.34		25.080^＊		29.58±5.62		18.88±5.13			23.712^＊
研究组	33.28±6.63		17.81±4.48		30.266^＊		30.62±6.09		16.64±4.57			29.737^＊
t	0.470		2.136^＊				0.823		2.138^＊

组别	CD3⁺/%						CD8⁺/%
组别	治疗前		治疗后		t		治疗前		治疗后			t
对照组	43.75±5.51		48.73±5.12		11.184^＊		32.30±3.24		30.26±3.13			7.668^＊
研究组	44.32±5.24		51.31±5.83		15.010^＊		32.36±3.31		29.05±2.94			12.566^＊
t	0.492		2.180^＊				0.085		2.021^＊
组别		CD4⁺/%						CD4⁺/CD8⁺
组别		治疗前		治疗后		t		治疗前		治疗后	t
对照组		42.64±4.03		49.32±5.11		16.851^＊		1.32±0.27		1.63±0.35	11.447^＊
研究组		41.42±4.34		51.71±5.52		24.039^＊		1.28±0.25		1.78±0.31	20.724^＊
t		1.351		2.083^＊				0.713		2.104^＊

组别	CD3⁺/%						CD8⁺/%
组别	治疗前		治疗后		t		治疗前		治疗后			t
对照组	43.75±5.51		48.73±5.12		11.184^＊		32.30±3.24		30.26±3.13			7.668^＊
研究组	44.32±5.24		51.31±5.83		15.010^＊		32.36±3.31		29.05±2.94			12.566^＊
t	0.492		2.180^＊				0.085		2.021^＊
组别		CD4⁺/%						CD4⁺/CD8⁺
组别		治疗前		治疗后		t		治疗前		治疗后	t
对照组		42.64±4.03		49.32±5.11		16.851^＊		1.32±0.27		1.63±0.35	11.447^＊
研究组		41.42±4.34		51.71±5.52		24.039^＊		1.28±0.25		1.78±0.31	20.724^＊
t		1.351		2.083^＊				0.713		2.104^＊

组别	TPO/（ng/L）
组别	治疗前			治疗后		t
对照组	126.75±18.37			220.72±25.07		48.619^＊
研究组	123.32±17.24			234.11±28.82		49.359^＊
t	0.893			2.299^＊
组别		IL-11/（ng/L）
组别		治疗前	治疗后		t
对照组		1.26±0.15	1.55±0.26		14.253^＊
研究组		1.31±0.14	1.69±0.32		14.433^＊
t		1.598	2.227^＊

重组人白细胞介素-11与海曲泊帕乙醇胺片对乳腺癌化疗所致血小板减少症的疗效对比

Comparison of efficacy of recombinant human interleukin-11 and herombopag olamine tablets on chemotherapy-induced thrombocytopenia in breast cancer

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 4

参考文献 20

相关文章 15

编辑推荐

Metrics

本文评价

组别	肌肉酸痛			乏力	发热		肝功能损伤
对照组	1（2.33）			2（4.65）	1（2.33）		0（0.00）
研究组	0（0.00）			3（6.98）	0（0.00）		2（4.65）
组别		腹泻	恶心呕吐			皮疹		总发生
对照组		1（2.33）	1（2.33）			1（2.33）		7（16.28）
研究组		0（0.00）	2（4.65）			2（4.65）		9（20.93）

[1]	李娜, 贺英, 滕飞, 贺文姝, 郭彩凤, 钟娜, 吴琼, 李军. 超声BI-RADS分类联合血清FGFR1、GDF3在乳腺肿块良恶性鉴别诊断中的应用价值[J]. 天津医药, 2025, 53(3): 247-251.
[2]	王伟, 夏海水, 马上. 曲妥珠单抗联合奈拉替尼治疗HER-2阳性转移性乳腺癌的疗效[J]. 天津医药, 2025, 53(3): 321-325.
[3]	王琳娜, 王迪, 董彦宏. 艾立布林联合NP方案治疗晚期乳腺癌患者的临床效果[J]. 天津医药, 2025, 53(3): 326-330.
[4]	王鑫, 赵晓静, 党琳, 门剑龙. 1例肝素诱导的血小板减少症患者多学科诊疗分析[J]. 天津医药, 2025, 53(2): 194-198.
[5]	朱刚明, 董永德, 朱瑞婷, 谭源满, 陶娟, 刘晓, 陈德成, 杨概. 磁共振弛豫时间定量成像预测乳腺浸润性导管癌分子亚型的价值[J]. 天津医药, 2024, 52(7): 770-774.
[6]	陈芷彦, 伍秋苑, 邓裕华, 周丹. 类器官技术在乳腺癌研究中的现状及应用[J]. 天津医药, 2024, 52(6): 668-672.
[7]	刘丹阳, 李永涛, 张海燕, 李林, 刘洋, 沈雷. 乳腺癌细胞条件培养基对骨髓间充质干细胞生物学行为的影响[J]. 天津医药, 2024, 52(5): 454-458.
[8]	谢皓冉, 李一浩, 刘成, 夏瑜婷, 裘圣蕾, 熊斌, 冯其贞. 医保DIP支付背景下乳腺癌腋窝淋巴结转移的预测因素探讨[J]. 天津医药, 2024, 52(11): 1193-1196.
[9]	吴海啸, 马文娟, 李之珺, 张超. 基于放射组学评估胸肌指数与乳腺癌骨转移患者预后关系的研究[J]. 天津医药, 2023, 51(9): 1007-1010.
[10]	杨娉娉, 张景, 陈红宇, 张淼, 周定安, 方文. 抑癌基因SASH1在乳腺癌中结合Vimentin并负性调节Vimentin的表达[J]. 天津医药, 2023, 51(9): 904-908.
[11]	赵津津, 王振宇, 马贞秀. circRASSF2靶向miR-1343-3p对乳腺癌MDA-MB-231细胞增殖和凋亡的影响[J]. 天津医药, 2023, 51(7): 713-717.
[12]	刘丹阳, 王璐璐, 何军, 姜杨, 李永涛, 张晓东, 李鹏辉, 沈雷. 乳腺癌细胞培养上清液促进人脂肪间充质干细胞迁移和增殖的机制探讨[J]. 天津医药, 2023, 51(11): 1153-1157.
[13]	周妮娜, 顾健辉, 杨治平, 盛俞, 姜荣. 小儿免疫性血小板减少症疾病转归的影响因素及风险预测模型构建[J]. 天津医药, 2023, 51(10): 1122-1125.
[14]	平静, 周东华, 朱大江, 田杰, 陈莹, 范菊花. Musashi2在不同分子分型乳腺浸润性导管癌中的表达及临床意义[J]. 天津医药, 2022, 50(9): 907-911.
[15]	张宇, 刘梁生, 马文娟, 韩敏, 朱鹰, 路红. 早期肿块型乳腺浸润性导管癌超声征象与分子分型的相关性研究[J]. 天津医药, 2022, 50(8): 853-858.